Gearoid M McMahon1, Xiaoxi Zeng, Sushrut S Waikar. 1. Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts2Framingham Heart Study, National Heart, Lung, and Blood Institute, and Center for Population Studies, Framingham, Massachusetts.
Abstract
IMPORTANCE: Rhabdomyolysis ranges in severity from asymptomatic elevations in creatine phosphokinase levels to a life-threatening disorder characterized by severe acute kidney injury requiring hemodialysis or continuous renal replacement therapy (RRT). OBJECTIVE: To develop a risk prediction tool to identify patients at greatest risk of RRT or in-hospital mortality. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 2371 patients admitted between January 1, 2000, and March 31, 2011, to 2 large teaching hospitals in Boston, Massachusetts, with creatine phosphokinase levels in excess of 5000 U/L within 3 days of admission. The derivation cohort consisted of 1397 patients from Massachusetts General Hospital, and the validation cohort comprised 974 patients from Brigham and Women's Hospital. MAIN OUTCOMES AND MEASURES: The composite of RRT or in-hospital mortality. RESULTS: The causes and outcomes of rhabdomyolysis were similar between the derivation and validation cohorts. In total, the composite outcome occurred in 19.0% of patients (8.0% required RRT and 14.1% died during hospitalization). The highest rates of the composite outcome were from compartment syndrome (41.2%), sepsis (39.3%), and following cardiac arrest (58.5%). The lowest rates were from myositis (1.7%), exercise (3.2%), and seizures (6.0%). The independent predictors of the composite outcome were age, female sex, cause of rhabdomyolysis, and values of initial creatinine, creatine phosphokinase, phosphate, calcium, and bicarbonate. We developed a risk-prediction score from these variables in the derivation cohort and subsequently applied it in the validation cohort. The C statistic for the prediction model was 0.82 (95% CI, 0.80-0.85) in the derivation cohort and 0.83 (0.80-0.86) in the validation cohort. The Hosmer-Lemeshow P values were .14 and .28, respectively. In the validation cohort, among the patients with the lowest risk score (<5), 2.3% died or needed RRT. Among the patients with the highest risk score (>10), 61.2% died or needed RRT. CONCLUSIONS AND RELEVANCE: Outcomes from rhabdomyolysis vary widely depending on the clinical context. The risk of RRT or in-hospital mortality in patients with rhabdomyolysis can be estimated using commonly available demographic, clinical, and laboratory variables on admission.
IMPORTANCE: Rhabdomyolysis ranges in severity from asymptomatic elevations in creatine phosphokinase levels to a life-threatening disorder characterized by severe acute kidney injury requiring hemodialysis or continuous renal replacement therapy (RRT). OBJECTIVE: To develop a risk prediction tool to identify patients at greatest risk of RRT or in-hospital mortality. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 2371 patients admitted between January 1, 2000, and March 31, 2011, to 2 large teaching hospitals in Boston, Massachusetts, with creatine phosphokinase levels in excess of 5000 U/L within 3 days of admission. The derivation cohort consisted of 1397 patients from Massachusetts General Hospital, and the validation cohort comprised 974 patients from Brigham and Women's Hospital. MAIN OUTCOMES AND MEASURES: The composite of RRT or in-hospital mortality. RESULTS: The causes and outcomes of rhabdomyolysis were similar between the derivation and validation cohorts. In total, the composite outcome occurred in 19.0% of patients (8.0% required RRT and 14.1% died during hospitalization). The highest rates of the composite outcome were from compartment syndrome (41.2%), sepsis (39.3%), and following cardiac arrest (58.5%). The lowest rates were from myositis (1.7%), exercise (3.2%), and seizures (6.0%). The independent predictors of the composite outcome were age, female sex, cause of rhabdomyolysis, and values of initial creatinine, creatine phosphokinase, phosphate, calcium, and bicarbonate. We developed a risk-prediction score from these variables in the derivation cohort and subsequently applied it in the validation cohort. The C statistic for the prediction model was 0.82 (95% CI, 0.80-0.85) in the derivation cohort and 0.83 (0.80-0.86) in the validation cohort. The Hosmer-Lemeshow P values were .14 and .28, respectively. In the validation cohort, among the patients with the lowest risk score (<5), 2.3% died or needed RRT. Among the patients with the highest risk score (>10), 61.2% died or needed RRT. CONCLUSIONS AND RELEVANCE: Outcomes from rhabdomyolysis vary widely depending on the clinical context. The risk of RRT or in-hospital mortality in patients with rhabdomyolysis can be estimated using commonly available demographic, clinical, and laboratory variables on admission.
Authors: Monica J Hubal; Joseph M Devaney; Eric P Hoffman; Edward J Zambraski; Heather Gordish-Dressman; Amy K Kearns; Justin S Larkin; Kasra Adham; Ronak R Patel; Priscilla M Clarkson Journal: J Appl Physiol (1985) Date: 2010-03-25
Authors: Priscilla M Clarkson; Eric P Hoffman; Edward Zambraski; Heather Gordish-Dressman; Amy Kearns; Monica Hubal; Brennan Harmon; Joseph M Devaney Journal: J Appl Physiol (1985) Date: 2005-04-07
Authors: Daliana Peres Bota; Christian Melot; Flavio Lopes Ferreira; Vinh Nguyen Ba; Jean-Louis Vincent Journal: Intensive Care Med Date: 2002-09-06 Impact factor: 17.440
Authors: Sushrut S Waikar; Ron Wald; Glenn M Chertow; Gary C Curhan; Wolfgang C Winkelmayer; Orfeas Liangos; Marie-Anne Sosa; Bertrand L Jaber Journal: J Am Soc Nephrol Date: 2006-04-26 Impact factor: 10.121
Authors: Priscilla M Clarkson; Amy K Kearns; Pierre Rouzier; Richard Rubin; Paul D Thompson Journal: Med Sci Sports Exerc Date: 2006-04 Impact factor: 5.411
Authors: Andrew S Allegretti; Xavier Vela Parada; Nwamaka D Eneanya; Hannah Gilligan; Dihua Xu; Sophia Zhao; Jules L Dienstag; Raymond T Chung; Ravi I Thadhani Journal: Clin J Am Soc Nephrol Date: 2017-11-09 Impact factor: 8.237
Authors: Andrew S Allegretti; Guillermo Ortiz; Jie Cui; Julia Wenger; Ishir Bhan; Raymond T Chung; Ravi I Thadhani; Zubin Irani Journal: Am J Kidney Dis Date: 2016-03-16 Impact factor: 8.860
Authors: Abhinav Sidana; Annerleim Walton-Diaz; Hong Truong; M Minhaj Siddiqui; Ning Miao; Johanna Shih; Andrew Mannes; Gennady Bratslavsky; W Marston Linehan; Adam R Metwalli Journal: Int Urol Nephrol Date: 2016-04-19 Impact factor: 2.370